Pramlintide
Also referenced as: Symlin
An amylin analogue used as an adjunct to mealtime insulin in selected adults with diabetes.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Symlin is FDA-approved as an adjunct in selected adults with type 1 or type 2 diabetes using mealtime insulin and inadequately controlled despite optimized insulin therapy.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An amylin analogue used as an adjunct to mealtime insulin in selected adults with diabetes.
Symlin is FDA-approved as an adjunct in selected adults with type 1 or type 2 diabetes using mealtime insulin and inadequately controlled despite optimized insulin therapy.
It is not interchangeable with investigational long-acting amylin analogues or independently approved as an obesity medicine.
Why It's Being Studied
- Insulin-treated diabetes
- Post-meal glucose
- Amylin signalling
Mechanism of Action
It slows gastric emptying, suppresses post-meal glucagon and promotes satiety.
It slows gastric emptying, suppresses post-meal glucagon and promotes satiety. It is not interchangeable with investigational long-acting amylin analogues or independently approved as an obesity medicine.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Insulin-treated diabetes
- Post-meal glucose
- Amylin signalling
- Subcutaneous approved medicine
Evidence Summary
Controlled studies support its adjunct glycemic role in insulin-treated type 1 or type 2 diabetes.
Higher tiers carry more weight. Filled tiers have evidence for Pramlintide; tap to read it.
- Controlled studies support its adjunct glycemic role in insulin-treated type 1 or type 2 diabetes.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Controlled studies support its adjunct glycemic role in insulin-treated type 1 or type 2 diabetes.
Reported Adverse Events in Research
- A boxed warning covers severe hypoglycemia with insulin; gastroparesis and hypoglycemia unawareness are contraindications.
Limitations of Current Evidence
- It is not interchangeable with investigational long-acting amylin analogues or independently approved as an obesity medicine.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Pramlintide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Pramlintide — prescribing label